These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18318942)

  • 21. Miltefosine--the long-awaited therapy for visceral leishmaniasis?
    Herwaldt BL
    N Engl J Med; 1999 Dec; 341(24):1840-2. PubMed ID: 10588972
    [No Abstract]   [Full Text] [Related]  

  • 22. Immunoglobulin for concurrent Guillain-Barré and immune thrombocytopenic purpura.
    Zeidman LA; Fahey CD; Grinblatt DL; Harsanyi K
    Pediatr Neurol; 2006 Jan; 34(1):60-2. PubMed ID: 16376282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral miltefosine in post-kala-azar dermal leishmaniasis--experience in three cases.
    Khandpur S; Chaturvedi P; Kumar U; Khaitan BK; Samantaray JC; Sharma VK
    Int J Dermatol; 2010 May; 49(5):565-9. PubMed ID: 20534094
    [No Abstract]   [Full Text] [Related]  

  • 24. Individual patients who experienced both Guillain-Barré syndrome and CIDP.
    Kuitwaard K; van der Pol WL; Ruts L; van Doorn PA
    J Peripher Nerv Syst; 2009 Mar; 14(1):66-8. PubMed ID: 19335542
    [No Abstract]   [Full Text] [Related]  

  • 25. Guillain-Barré syndrome and its variants: a case of acute motor-sensory axonal neuropathy in Jamaica.
    Fletcher-Peddie K; Alfred R; Penn-Brown K; Gayle F; Gilbert DT; Elliot V; Ferguson TS
    West Indian Med J; 2013 Sep; 62(7):658-66. PubMed ID: 24831908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Visceral leishmaniasis simulating chronic liver disease: successful treatment with miltefosine.
    Avasthi R; Chaudhary SC; Khanna S
    Indian J Med Microbiol; 2009; 27(1):85-6. PubMed ID: 19172077
    [No Abstract]   [Full Text] [Related]  

  • 27. One-year follow-up of immunocompetent male patients treated with miltefosine for primary visceral leishmaniasis in Bihar, India.
    Burza S; Nabi E; Mahajan R; Mitra G; Lima MA
    Clin Infect Dis; 2013 Nov; 57(9):1363-4. PubMed ID: 23943824
    [No Abstract]   [Full Text] [Related]  

  • 28. Atypical disseminated leishmaniasis resembling post-kala-azar dermal leishmaniasis in an HIV-infected patient.
    Boumis E; Chinello P; Della Rocca C; Paglia MG; Proietti MF; Petrosillo N
    Int J STD AIDS; 2006 May; 17(5):351-3. PubMed ID: 16643688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of visceral leishmaniasis: efficacy and limits of miltefosine].
    Gangneux JP; Marty P
    Sante; 2001; 11(4):257-8. PubMed ID: 11861203
    [No Abstract]   [Full Text] [Related]  

  • 30. Posterior reversible encephalopathy syndrome associated with IVIG in a patient with Guillain-Barré syndrome.
    Koichihara R; Hamano S; Yamashita S; Tanaka M
    Pediatr Neurol; 2008 Aug; 39(2):123-5. PubMed ID: 18639758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An unwelcome synergy: leishmaniasis and HIV.
    Colasanti J; Altamirano J; Espinoza L
    Am J Med; 2013 Feb; 126(2):114-6. PubMed ID: 23331437
    [No Abstract]   [Full Text] [Related]  

  • 32. Combination therapy with amphotericin-B and miltefosine for post-kala-azar dermal leishmaniasis: a preliminary report.
    Ramesh V; Avishek K; Sharma V; Salotra P
    Acta Derm Venereol; 2014 Mar; 94(2):242-3. PubMed ID: 23995012
    [No Abstract]   [Full Text] [Related]  

  • 33. Kala-azar--progress against a neglected disease.
    Murray HW
    N Engl J Med; 2002 Nov; 347(22):1793-4. PubMed ID: 12456856
    [No Abstract]   [Full Text] [Related]  

  • 34. Post-kala-azar dermal Leishmaniasis and uveitis in an HIV-positive patient.
    Ramos A; Cruz I; Muñez E; Salas C; Fernández A; Alvarez-Espejo T
    Infection; 2008 Mar; 36(2):184-6. PubMed ID: 18327683
    [No Abstract]   [Full Text] [Related]  

  • 35. Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration.
    Manfredi R; Marinacci G; Calza L; Passarini B
    Int J Antimicrob Agents; 2008 Jun; 31(6):590-2. PubMed ID: 18456464
    [No Abstract]   [Full Text] [Related]  

  • 36. Challenges in HIV and visceral Leishmania co-infection: future research directions.
    Ejara ED; Lynen L; Boelaert M; Van Griensven J
    Trop Med Int Health; 2010 Oct; 15(10):1266-7. PubMed ID: 20723183
    [No Abstract]   [Full Text] [Related]  

  • 37. Guillain-Barré syndrome: a common neurological entity with myriad manifestations.
    Nadkar MY; Bajpai S; Itolikar M
    J Assoc Physicians India; 2013 Mar; 61(3):165-6. PubMed ID: 24475677
    [No Abstract]   [Full Text] [Related]  

  • 38. [Visceral leishmaniasis: a new oral treatment?].
    Minodier P; Nicaise C; Gire C; Garnier JM
    Arch Pediatr; 1999 Jun; 6(6):687-8. PubMed ID: 10394465
    [No Abstract]   [Full Text] [Related]  

  • 39. Oral miltefosine in the treatment of kala-azar.
    Mohan A; Seth S
    Natl Med J India; 2000; 13(4):202-3. PubMed ID: 11002688
    [No Abstract]   [Full Text] [Related]  

  • 40. Current diagnosis and treatment of visceral leishmaniasis.
    Mondal S; Bhattacharya P; Ali N
    Expert Rev Anti Infect Ther; 2010 Aug; 8(8):919-44. PubMed ID: 20695748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.